Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven in Healthy Males
NCT02084810Phase 1Withdrawn
- Sponsor
- Novo Nordisk
- Start
- Mar 2014
- Primary completion
- Jul 2014
01
Overview
Phase 1, randomised, double-blind trial of coagulation factor VIIa in hemophilia A and hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Area under the curve at 36 hours and Maximum concentration at 36 hours. Planned start Mar 2014; status: withdrawn.
02
Drugs
coagulation factor VIIa
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT02084810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02084810.